Compare ZD & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZD | VCEL |
|---|---|---|
| Founded | 1995 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 1999 | 1996 |
| Metric | ZD | VCEL |
|---|---|---|
| Price | $50.04 | $58.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $63.20 | ★ $65.43 |
| AVG Volume (30 Days) | 412.2K | ★ 819.8K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 17.22 | 0.19 |
| Revenue | ★ $1,364,028,000.00 | $276,259,000.00 |
| Revenue This Year | N/A | $24.98 |
| Revenue Next Year | N/A | $15.37 |
| P/E Ratio | ★ $2.98 | $308.26 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $22.45 | $28.95 |
| 52 Week High | $60.48 | $59.75 |
| Indicator | ZD | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 37.51 | 73.98 |
| Support Level | $46.65 | $31.94 |
| Resistance Level | $50.55 | $59.75 |
| Average True Range (ATR) | 2.37 | 2.51 |
| MACD | -0.25 | 0.62 |
| Stochastic Oscillator | 29.36 | 92.37 |
Ziff Davis Inc is a digital media and internet company operating a portfolio of brands across technology, shopping, gaming and entertainment, health and wellness, connectivity, and cybersecurity. The company has five reportable segments. The Technology & Shopping segment generates revenue from advertising and commerce content. The Gaming & Entertainment segment provides content, subscriptions, and digital storefront services. The Health & Wellness segment offers digital tools and content for health management. The Connectivity segment provides data and analytics solutions for network performance. The Cybersecurity & Martech segment delivers cloud-based software for security and marketing. It generates the majority of its revenue from the Health & Wellness segment.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.